Work

Abstract 1729: An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study

Year: 2012

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2012-1729

Authors: Scott Rodig, Lecia V. Sequist, Joan H. Schiller, Yinpu Chen, Abdel Halim, Carol Waghorne, Hamim Zahir, Brian Schwartz

Institutions: Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Daiichi Sankyo (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2054965644

Cites:

Cited by: 10

Related to: 10